🇺🇸 FDA
Patent

US 11925675

Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy

granted A61KA61K38/177A61K48/0058

Quick answer

US patent 11925675 (Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K38/177, A61K48/0058, A61K48/0066, A61P